HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. filed for an IPO in Hong Kong late last week, making it the 11th biopharma company to seek a listing on the Hong Kong Stock Exchange (HKEX) since May and following Ascentage Pharma Group International's IPO a week earlier.
HONG KONG – South Korea's JW Pharmaceutical Corp. out-licensed its atopic dermatitis candidate, JW-1601, to Danish medical dermatologist Leo Pharma A/S, which has rights to develop and commercialize the drug worldwide, except in South Korea.
HONG KONG – The latest Chinese biopharma company to join the listing spree in Hong Kong was Suzhou-based Ascentage Pharma Group International, which last week filed its application to list on the Hong Kong Stock Exchange (HKEX).
HONG KONG – Roche Holding AG was granted a rapid approval from the China National Drug Administration (CNDA) for Alecensa (alectinib). The drug was greenlighted as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (NSCLC).
HONG KONG – Taiwan Liposome Co. Ltd. said its lead product candidate TLC-599, to treat osteoarthritis pain, has demonstrated promising results in its phase II study, making it a potential best-in-class intra-articular steroid for its duration of action.
HONG KONG – Jiangsu Hengrui Medicine Co. Ltd. said the China National Drug Administration (CNDA) granted a conditional approval to its self-developed compound pyrotinib for treating HER2-positive breast cancer. The approval was based on clinical data from phase II studies, demonstrating China's effort in marketing domestic innovative drugs faster.
HONG KONG – Roche Holding AG was granted a rapid approval from the China National Drug Administration (CNDA) for Alecensa (alectinib). The drug was greenlighted as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (NSCLC).
HONG KONG – Taiwan Liposome Co. Ltd. said its lead product candidate TLC-599, to treat osteoarthritis pain, has demonstrated promising results in its phase II study, making it a potential best-in-class intra-articular steroid for its duration of action.
HONG KONG – The latest Chinese biopharma company to join the listing spree in Hong Kong was Suzhou-based Ascentage Pharma Group International, which last week filed its application to list on the Hong Kong Stock Exchange (HKEX).
HONG KONG – Canbridge Life Sciences Ltd., of Beijing, said it would soon initiate a phase Ib/III clinical study of its monoclonal antibody candidate CAN-017 in esophageal squamous cell cancer (ESCC). The multicenter study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CAN-017 in combination with chemotherapy as the second-line treatment for patients with locally advanced or metastatic ESCC.
